Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF)'s chief executive, Dr Markku Jalkanen, will present at the 42nd Annual JP Morgan Healthcare Conference in San Francisco on 11 January, with the presentation accessible on www.faron.com. The clinical-stage company is developing a unique immunotherapy with the potential to remove immunosuppression of cancers through targeting myeloid cell function.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com